

Features

- Medicinal chemistry case studies of ion channels as therapeutic targets
- Advances in structure determination techniques and successful structure determinations of key ion channels
- Novel pharmacology and target validation
- Emerging technologies for targeting, assaying and modulating ion channel targets
- Plenary speakers, poster session, trade exhibition, on-site accommodation and dinner

Registration

Registration is open, and fees include the conference dinner at the Wellcome Genome Campus on Monday evening. Early-bird rates for payments received by 29th November:

£300 Member of the RSC or SCI

£350 Non-member

£135 Student* member of the RSC or SCI

£160 Student* non-member

* Student is an undergraduate or postgraduate, not post-doc

Students and Bursaries

Discounted registration fees are available for students, and some student bursaries will be available from the RSC and SCI.

Venue and Travel

Address: Wellcome Genome Campus
Conference Centre, Hinxton, Cambridge
CB10 1RQ, UK.

By air: Stansted airport is 20 minutes' drive,
London City and Luton are 60 minutes, and
Heathrow and Gatwick are 90 minutes.
Additional travel information may be found on
our website.

Accommodation

Limited rooms are available at the conference venue, for both Sunday and Monday nights, in Mulberry and Willow Courts. These rooms can be booked using the link and booking code on the conference website: a single occupancy en-suite room is £102 per night, bed and breakfast.

Exhibitors

There will be a relevant trade exhibition. Stand space will measure 3 m wide x 2 m deep, and include a table, chair, electrical and wi-fi access. The charge is £900 for exhibition stand space and this rate includes one full delegate attendee with conference dinner.

Sponsors

Sponsors are encouraged to support this well-respected event, and we are grateful to our confirmed sponsors: Evotec, Enterprise Therapeutics, SB Drug Discovery, and Metrion Biosciences.

Call for Abstracts

Abstracts are invited for posters and two "late-breaker" oral presentations. The closing date is 15th November.

Posters will be displayed throughout the meeting, and there will be the option to give a two-minute oral "flash" presentation. There will be a dedicated poster session on Monday evening.

Organising Committee

Karl Collins, Bayer
Brian Cox, University of Sussex
Ged Giblin, Giblin Consultancy
Sarah Major, Charnwood Molecular (Chair)
Nigel Swain, Heptares
Jason Tierney, Top Tier Consultancy



INVENTING FOR LIFE

Secretariat Contact

Maggi Churchouse Events
Tel +44 (0)1359 221004

Maggi@maggichurhouseevents.co.uk

<https://www.maggichurhouseevents.co.uk/bmcs>

www.rsc.org/bmcs www.soci.org/events

Twitter Hashtag
#IonChannels20

Third Announcement and Call for Abstracts

Image originally created by Dr Wojciech Kopec

6th RSC / SCI Symposium on Ion Channels as Therapeutic Targets

Monday-Tuesday, 24th-25th February 2020

Wellcome Genome Campus
Cambridge, UK



Organised by:
RSC Biological and Medicinal Chemistry Sector and
SCI Fine Chemicals Group

Ion Channels as Therapeutic Targets

Synopsis

Ion channels are important targets for therapeutic intervention due to their extensive roles in human physiology and the pathophysiology of disease. Many successful drugs targeting this gene family have been discovered for diseases such as hypertension, epilepsy and neuropathic pain.

This symposium, the 6th in an ongoing series, will showcase the most recent advances to aid the design of new ion channel therapeutics and promote interaction between scientists with a shared interest in the field of ion channel drug discovery.

Who should attend

Scientists from industry and academia interested in the therapeutic potential of ion channels. The organising committee particularly welcomes attendance and participation of students working in the field of ion channel research.

Programme

Monday, 24th February

- 10.00 Registration and refreshments
- 10.30 *Opening remarks*
Sarah Major, Charnwood Molecular (chair of the Organising Committee)
- 10.40 Keynote presentation: *Ion channel drug discovery - fading star or shining light?*
Martin Gosling, Enterprise Therapeutics
- 11.20 *The discovery of novel NGLu2B-selective negative allosteric modulators for the treatment of depression*
Michael Letavic, Janssen Research & Development
- 12.00 *The discovery and optimisation of triazine-oxadiazoles as inhibitors of Na_v1.7*
Jonathan Bentley, Evotec
- 12.30 Lunch, exhibition and posters
- 13.30 *Understanding and manipulating the Piezo1 force sensor in health and disease*
David Beech, University of Leeds
- 14.10 *Please take off your coat: how naked ions ensure rapid and selective potassium channel permeation*
Ulrich Zachariae, School of Life Sciences, University of Dundee
- 14.50 *Development of small molecule inhibitors of the Orai1 channel as potential therapeutics for cardiovascular diseases*
Katherine Norman, University of Leeds
- 15.00 *Insight into the cytoplasmic domain of HCN2 from a gain-of-function mutation*
Genevieve Evans, KU Leuven, Belgium
- 15.10 Flash poster presentations
- 15.22 Refreshments, exhibition and posters



#IonChannels20

Ion Channels as Therapeutic Targets

Monday, 24th February

- 15.50 *Latest drug developments in the field of ion channels*
Andrea Brüggemann, Nanion Technologies
- 16.20 *Screening, de-risking and enhancing the therapeutic potential of K2P channels as small molecule drug discovery targets*
Jonathan Large, LifeArc
- 16.50 *Discovery of small molecule scaffolds that improve stability and restore function to the F508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) anion channel*
Phil Kym, Abbvie
- 17.30 Networking reception, exhibition and posters
- 19.00 Conference dinner at the Wellcome Genome Campus

Tuesday, 25th February

- 08.30 Refreshment, exhibition and posters
- 09.00 *An unusual lower X-gate in the TASK-1 channel leads to compound trapping*
Liz Carpenter, Structural Genomics Consortium
- 09.40 *Application of physiological multidimensional SAR (MuDiSAR) for identification of novel TASK1 inhibitors by uHTS*
Thomas Müller, Bayer
- 10.10 Refreshments, exhibition and posters
- 10.40 *The development of a potent and selective agonist of human TRPM5 possessing in vivo gastrointestinal pro kinetic efficacy*
Mark Sabat, Takeda Pharmaceuticals
- 11.10 *Understanding potent small-molecule modulation of TRPC1/4/5 channels*
Robin Bon, University of Leeds
- 11.50 *Novel CIC-1 Chloride Channel Blockers for the treatment of neuromuscular disorders*
Anders Riisager and Lars Knutsen, NMD Pharma
- 12.30 Lunch, exhibition and posters
- 13.35 Poster prize presentations
- 13.45 *Discovery of potent and selective state-dependent Cav2.2 channel modulators with efficacy in preclinical pain models and human tissue: novel non-opioid analgesics*
Marc Rogers, Metrion Biosciences Ltd
- 14.15 *The discovery of TMEM16A potentiators: a novel approach to treat cystic fibrosis lung disease*
Henry Danahay, Enterprise Therapeutics
- 14.25 Keynote presentation: *Human GABA_A receptor structures and signalling mechanisms*
Radu Aricecu, MRC Laboratory of Molecular Biology
- 15.35 Closing remarks
- 15.55 Close